Skip to main content
. 2010 Nov;5(11):2075–2084. doi: 10.2215/CJN.01190210

Figure 2.

Figure 2.

Renal survival in patients with and without pathogenic mutations in podocyte genes. Development of ESRD was 29% in patients without pathogenic mutation compared with 71% in patients with proven mutation (P = 0.0001; Fisher's exact test). Sixty-three percent (nongenetic) compared with 22% (genetic) of the patients preserved a normal renal function over the mean follow-up time of the study (8.6 years).